TargetBeta
TLR2
toll like receptor 2 · also TIL4, CD282 · CD molecules
2 programs in company-led studies act on TLR2, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- COVID-19, 1 program
- Influenza, Human, 1 program
- Parkinson Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 12, 2027INNA-051 · ENA Respiratory Pty · phase 2 · NCT07222670
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.